Loading…
Lobbying Spend
—
Filings
13
Firms Hired
1
Active Period
2012–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.2617
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2022 · fourth_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4043
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2022 · third_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Client expense: — · Firm income: $50,000
Matched citations: H.R.4043
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Client expense: — · Firm income: $50,000
Matched citations: H.R.6833
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2022 · second_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4043
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2022 · first_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021; MDUFA Reauthorization.
Client expense: — · Firm income: $30,000
Matched citations: H.R.4043
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2021 · fourth_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4043
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2021 · third_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021.
Client expense: — · Firm income: $20,000
Matched citations: H.R.4043
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
2021 · third_quarter · Firm: OGR
Issues related to Medicare coverage of health technologies and services; Medicare Coverage for Innovative Technology Rule; H.R.4043, Ensuring Patient Access to Critical Breakthrough Products Act of 2021.
Client expense: — · Firm income: —
Matched citations: H.R.4043
Food and Drug Administration Reform Act of 2012
2012 · fourth_quarter · Firm: OGR
S.3187/H.R.5651, Food and Drug Administration Safety and Innovation Act (Public Law No: 112-144); Medical Device User Fee Act and related issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5651
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: OGR
S.3187/H.R.5651, Food and Drug Administration Safety and Innovation Act (Public Law No: 112-144); Medical Device User Fee Act and related issues.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5651
Source: Senate LDA